OVs combined with epigenetic drugs, CRISPR-based reprogramming + PARP inhibitors (e.g. Olaparib) + HDAC inhibitors; or PARP inhibitors (Olaparib) + AR-targeted therapies or IDH inhibitors + HDAC inhibitors for glioblastomas. Here, HDAC9 is linked to glioblastoma.